COMMUNIQUÉS West-GlobeNewswire

Iantrek Announces Commercial Launch of AlloFlo™ Uveo, the Only Surgical Treatment Targeting the Uveoscleral Pathway in Glaucoma
14/10/2025
AlloFlo™ Uveo expands interventional options for glaucoma surgeons and patients With over 100 surgeon partners and thousands of cases performed throughout the early-release program, Iantrek pioneers a new era in [...]
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
14/10/2025
SAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and [...]
Assembly Biosciences Announces Upcoming Investor Conference Participation
14/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that [...]
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
14/10/2025
The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 22-26 in Boston, Massachusetts ROCKVILLE, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the [...]
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
14/10/2025
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems [...]
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
14/10/2025
Non-inferiority trial versus PAXLOVID ® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment Separate single- [...]
BPGbio Welcomes Sheikh Dr. Khalid Bin Jabor Al Thani as Executive in Residence
14/10/2025
Distinguished cancer leader to advise BPGbio leadership on acceleration of NAi platform globally and BPM 31510 oncology franchise for Precision Oncology Initiatives BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc [...]
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
14/10/2025
MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the [...]
AB Science tiendra une conférence virtuelle le jeudi 16 octobre 2025, de 14 h à 15 h CET, afin de faire le point sur l'étude de phase 1 avec AB8939
14/10/2025
COMMUNIQUE DE PRESSE AB SCIENCE COMMUNIQUE LES PREMIERES DONNÉES DE COMBINAISON DE AB8939 AVEC VENETOCLAX : LES TROIS PREMIERS PATIENTS ATTEINTS D’UNE LEUCEMIE MYEOLIDE AIGUES (LMA) ASSOCIES A UN PROFIL GENETIQUE TRES [...]
AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
14/10/2025
PRESS RELEASE AB SCIENCE RELEASES INITIAL DATA ON THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA (AML): THE FIRST THREE PATIENTS, ALL OF WHOM HAVE AML WITH [...]
Peer Reviewed Publication Provides Evidence for Iron Dysregulation as a Driver of Dry AMD/GA and the Potential of Transferrin to Restore Iron Balance, Reinforcing PulseSight’s Therapeutic Strategy for PST-611
14/10/2025
PARIS, Oct. 14, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, a clinical stage ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology welcomes [...]
CancerVax Precision Therapy Successfully Avoids Healthy Liver Cells
14/10/2025
In-vitro studies confirm that the Company’s novel Smart mRNA could drastically reduce off-target liver toxicity, a major issue affecting many cancer drugs Lehi, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, October 14, [...]
EVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseases
14/10/2025
Press Release Press Release EVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseases Through this funding round, the company will initiate the clinical development of its first therapeutic [...]
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
14/10/2025
ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic [...]
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
14/10/2025
ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic [...]
Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
14/10/2025
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the [...]
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
14/10/2025
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. [...]
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
14/10/2025
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose [...]
Apollomics, Inc. Company Operational Continuity Update
14/10/2025
FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update. Apollomics is a clinical-stage [...]

Pages